Schrödinger (SDGR) News
Market Cap: $1.93B
Avg Volume: 1.19M
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Schrödinger to Announce First Quarter 2025 Financial Results on May 7
NEW YORK--(BUSINESS WIRE)--Schrödinger will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the financial markets close.
businesswire.com
Read More
3 Momentum Stocks That Could Soar Post-Market Volatility
While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground.
marketbeat.com
Read More
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2025, the company granted (i) a non-statutory stock option to purchase 3,300 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 12,866 shares of the company's common stock to six newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of.
businesswire.com
Read More
Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) strongly supports the U.S. Food and Drug Administration's (FDA) plan to reduce, refine or potentially replace current animal testing requirements with new approaches designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation. The FDA's roadmap encourages a number of computational approaches to predict drug properties. Schrödinger's widely used computational platform enables highly accur.
businesswire.com
Read More
Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last?
Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
zacks.com
Read More
Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)
Schrödinger's stock surged after the FDA's initiative to phase out animal testing, benefiting its computational drug discovery platform. The company has strong collaborations with big pharma and a promising internal pipeline, despite past financial struggles and intense competition. Schrödinger's predictive toxicology initiative aligns with regulatory trends, enhancing drug development efficiency and safety.
seekingalpha.com
Read More
Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025.
businesswire.com
Read More
Schrödinger: Still Waiting On A Catalyst
Schrödinger's Q4 2024 results and 2025 guidance were solid, yet the company's share price remains low due to ongoing losses. Cash burn is likely to moderate going forward, as investments in the company's internal pipeline have now stabilized. Regardless, cash burn concerns are misplaced, as Schrödinger has demonstrated that it can manage its liquidity position through things like partnerships and licensing.
seekingalpha.com
Read More
Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Affairs Ramy Farid - President & Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President, R&D & Therapeutics Conference Call Participants Kyle Yang - Jefferies CJ Yeh - Leerink Partners Brendan Smith - TD Cowen Michael Ryskin - Bank of America Vikram Purohit - Morgan Stanley Malcolm Hoffman - BMO Capital Markets Matt Hewitt - Craig-Hallum Capital Group Chris Shibutani - Goldman Sachs Operator Thank you for standing by. Welcome to Schrödinger's conference call to review Fourth Quarter and Full Year 2024 Financial Results.
seekingalpha.com
Read More
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.32 per share a year ago.
zacks.com
Read More
Schrödinger to Participate in Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced that management will participate in the following conferences in March: TD Cowen 45th Annual Health Care Conference: Fireside chat on Tuesday, March 4, 2025 at 10:30 a.m. E.T. Leerink Partners Global Biopharma Conference 2025: Fireside chat on Monday, March 10, 2025 at 3:40 p.m. E.T. KBCM Healthcare Forum: Fireside chat on Tuesday, March 18, 2025 at 9:00 a.m. E.T. The live discussions can be accessed in the “Investors” sectio.
businesswire.com
Read More
Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26
NEW YORK--(BUSINESS WIRE)--Schrödinger will report its fourth quarter and full-year 2024 financial results on Wednesday, February 26, 2025, after the financial markets close.
businesswire.com
Read More
Schrodinger (SDGR) Moves 14.1% Higher: Will This Strength Last?
Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
zacks.com
Read More
Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today provided an update on its progress across the business in 2024 and announced its strategic priorities for 2025. “We are very proud of our accomplishments in 2024. We advanced the capabilities of our computational platform and leveraged the synergies in our business, which included signing a multi-target research collaboration and expanded software licensing agreement with Novartis. We are pleased another innovative pharmaceutical.
businesswire.com
Read More
Schrödinger Broadens and Accelerates Predictive Toxicology Initiative
NEW YORK--(BUSINESS WIRE)--Schrödinger broadens and accelerates predictive toxicology initiative.
businesswire.com
Read More
Schrodinger price target raised to $28 from $27 at Goldman Sachs
Goldman Sachs raised the firm's price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company's Q3 results and announced deal with Novartis (NVS) involving both a research and expanded software utilization collaboration drove the stock higher, and while operating results from the quarter came in slightly below expectations, the management relayed confidence in the forward outlook for the balance of the year for the company's Software business, noting resiliency across large and mid-sized ACV accounts with increasing depth of utilization, the analyst tells investors in a research note. Schrodinger -0.165 (-0.74%) Novartis -1.08 (-1.03%)
https://thefly.com
Read More
Schrödinger (SDGR) Q3 2024 Earnings Call Transcript
Schrödinger Inc. (NASDAQ:SDGR ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Ramy Farid - President, Chief Executive Officer Karen Akinsanya - President, R&D and Therapeutics Geoff Porges - Chief Financial Officer Jaren Madden - Senior Vice President, Corporate Affairs and Investor Relations Conference Call Participants Matt - Jefferies Mani Foroohar - Leerink Partners Steve - Keybanc Gaspa - Morgan Stanley Evan Seigerman - BMO Capital Markets Joe Catanzaro - Piper Sandler Toff - Craig Hallum Brendan Smith - TD Cowen Sean Kim - Bank of America John - Citi Operator Welcome to Schrödinger's conference call to review our third quarter 2024 financial results. My name is Madison and I will be your Operator for today's call.
seekingalpha.com
Read More
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.86 per share a year ago.
zacks.com
Read More
Schrödinger Reports Third Quarter 2024 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the third quarter of 2024 and provided a business update.
businesswire.com
Read More
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced a multi-target collaboration and expanded software licensing agreement with Novartis.
businesswire.com
Read More
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in synergistic anti-tumor activity that leads to deeper and more durable responses compared to inhibitors that target only Wee1 or Myt1. The preclinical data also show that SGR-3515 has a favorable ph.
businesswire.com
Read More
Kuehn Law Encourages Investors of Schrodinger, Inc. to Contact Law Firm
NEW YORK , Sept. 19, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Schrodinger, Inc. (NASDAQ: SDGR) breached their fiduciary duties to shareholders.
prnewswire.com
Read More
2 Bill Gates stocks to turn $100 into $1,000 by 2025
Bill Gates has been named the world's richest man a record 18 times. Although the billionaire has shifted his focus to philanthropic efforts as time has gone on, the Bill & Melinda Gates Foundation Trust still relies on stock investments to finance its worthwhile goals.
finbold.com
Read More
The 3 Best Med Tech Stocks to Buy Now
According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and health information systems.” The organization reports that these firms favorably change health care with “earlier disease detection, less-invasive procedures, and more effective treatments.
investorplace.com
Read More
Schrödinger, Inc. (SDGR) Q2 2024 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Communications Ramy Farid - President & Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President R&D, Therapeutics Conference Call Participants Michael Yee - Jefferies Scott Schoenhaus - KeyBanc Conor McKay - BMO Capital Markets David Leibowitz - Citi Matt Hewitt - Craig-Hallam Capital Chris Shibutani - Goldman Sachs Steven Mah - TD Cowen Operator Thank you for standing by. Welcome to Schrödinger's Conference Call to review our Second Quarter 2024 Financial Results.
seekingalpha.com
Read More
Compared to Estimates, Schrodinger (SDGR) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Schrodinger (SDGR) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
Read More
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.21 per share a year ago.
zacks.com
Read More
3 Small-Cap Stocks to Buy at a 52-Week Low
Small-cap stocks have taken a beating in the last two years. After the meme stock craze of 2021 died down, investors found they could get more predictable thrills from large-cap technology stocks.
investorplace.com
Read More
Earnings Preview: Schrodinger, Inc. (SDGR) Q2 Earnings Expected to Decline
Schrodinger (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Read More
3 Stocks That Could Benefit Big Time From Coming Interest Rate Cuts
Inflation is trending downward and approaching the Federal Reserve's 2% target and unemployment is heading higher. The Fed is widely expected to begin cutting interest rates at its September meeting.
investorplace.com
Read More
3 Top-Rated Gene Editing Stocks Actually Making Money
Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR-Cas9.
investorplace.com
Read More
Schrodinger: Buy The Drug-Discovery Platform And Get The Pipeline Nearly For Free
Schrödinger is a hybrid biopharma company specializing in physics-based computational chemistry and traditional drug development. The company aims to utilize computational methods to create better drug candidates and improve strategic decision-making in clinical trials. Schrödinger has attracted substantial investment from strategic partnerships and has a diverse pipeline of drug candidates in clinical development.
seekingalpha.com
Read More
1 Growth Stock That Could Dominate AI's Next Breakthrough
Highlights from analysis from 24/7 Wall Street Analysts Eric Bleeker and Austin Smith can be found below.
247wallst.com
Read More
Schrödinger to Present at Jefferies Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference.
businesswire.com
Read More
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
It's no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stocks?
investorplace.com
Read More
What's the Difference Between Biotech Stocks and TechBio Stocks?
Some high-tech biotechs claim to be "TechBio" companies. The term signals the use of an automation-heavy approach to biotech.
fool.com
Read More
Schrödinger, Inc. (SDGR) Q1 2024 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Ramy Farid - President and CEO Geoff Porges - CFO Karen Akinsanya - President R&D, Therapeutics Jaren Madden - Senior Vice President, Investor Relations and Corporate Communications Conference Call Participants Michael Yee - Jefferies David Leibowitz - Citi Scott Schoenhaus - KeyBanc Vikram Purohit - Morgan Stanley Conor McKay - BMO Steven Mah - TD Cowen Michael Ryskin - Bank of America Matthew Hewitt - Craig-Hallam Capital Joseph Catanzaro - Piper Sandler Chris Shibutani - Goldman Sachs Operator Welcome to Schrödinger's Conference Call to review First Quarter and 2024 Financial Results. My name is Claudette [ph], and I will be your operator for today's call.
seekingalpha.com
Read More
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.76 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.38 per share a year ago.
zacks.com
Read More
Schrödinger Reports First Quarter 2024 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the first quarter of 2024.
businesswire.com
Read More
Schrödinger to Announce First Quarter 2024 Financial Results on May 1
NEW YORK--(BUSINESS WIRE)--Schrödinger will report its first quarter 2024 financial results on Wednesday, May 1, 2024, after the financial markets close.
businesswire.com
Read More
5 Healthcare Stocks to Buy for 2024
What has been the top-performing stock so far of 2024? If you had said server installer Super Micro Computer (NASDAQ: SMCI ), that would be a great answer.
investorplace.com
Read More
Invest Like Bill Gates With These 3 AI Stocks to Buy
Bill Gates' old company, Microsoft (NASDAQ: MSFT ), would undoubtedly be on his list of AI stocks to buy. I suspect it's on most AI investors' must-own list.
investorplace.com
Read More
Shhh! 7 Small-Cap Stocks That Can Double by 2025
Small cap stocks like those discussed below tend to receive much less attention than their large cap competitors. Shares, which boast a market capitalization between $250 million and $2 billion, remain relatively small.
investorplace.com
Read More
The Hot List: 3 AI Stocks Worth Buying on Weakness
Wall Street has correctly recognized that artificial intelligence (AI) is a game-changer. It enables individuals to use computers more easily than ever before to find the best answers to complex questions.
investorplace.com
Read More
Schrodinger, Inc. (SDGR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Schrodinger, Inc. (SDGR) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
Read More
Schrödinger, Inc. (SDGR) Q4 2023 Earnings Call Transcript
Schrödinger, Inc. (SDGR) Q4 2023 Earnings Call Transcript
seekingalpha.com
Read More
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago.
zacks.com
Read More
Countdown to Schrodinger, Inc. (SDGR) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for Schrodinger, Inc. (SDGR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
zacks.com
Read More
Double Your Money: 3 Growth Stocks to Grab in 2024
The near- and medium-term outlooks for growth stocks have greatly improved in recent weeks. That's because it appears that the Street has, at long last, realized that relatively small increases in interest rates don't necessarily portend doom for all growth names.
investorplace.com
Read More
Artificial Intelligence in Healthcare: 3 Stocks Transforming the Industry
Artificial intelligence is being applied across the healthcare sector to improve delivery overall. AI stocks have the potential to impact stock sectors across the market positively, and healthcare is no different in that regard.
investorplace.com
Read More
3 Cutting-Edge Biotech Stocks for the Bold Investor
Ahead of what could be significant uncertainties in the market, investors may be better served with cutting-edge biotech stocks. Fundamentally, the reasoning centers on relative insulation.
investorplace.com
Read More
AI Alert: 3 Healthcare Stocks That Are Investing in Artificial Intelligence
We're still in the initial stages of a massively disruptive artificial intelligence ( AI ) boom. Big Tech is investing billions of dollars into it.
investorplace.com
Read More
Schrodinger: Attractive Risk-Reward
Customers in the biopharma industry are cutting spending, creating a soft demand environment for Schrodinger's software and drug discovery services. Despite the recent share price spike, Schrodinger's valuation is still low when accounting for all of the company's assets (cash, equity, milestones, royalties, software business). While Schrodinger's stock should do well long-term, growth is likely to remain weak in the near term and losses will remain high while the company invests in its proprietary pipeline.
seekingalpha.com
Read More
3 Top Publicly Traded Companies Leading the AI Revolution
Better-than-expected labor productivity data for the U.S. economy reported on Nov. 2 was the reason behind the huge stock market rally that day. “Non-farm productivity, which measures hourly output per worker, increased at a 4.7% annualized rate,” Reuters reported.
investorplace.com
Read More
Is Schrödinger Stock a Buy Now?
Schrödinger helps drugmakers discover high-quality leads for drug development. It has a star-studded cast of collaborators already, but it isn't growing much.
fool.com
Read More
Schrödinger, Inc. (SDGR) Q3 2023 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR ) Q3 2023 Results Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations and Corporate Communications Ramy Farid - President and Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President R&D, Therapeutics Conference Call Participants Michael Yee - Jefferies LLC Malcolm Hoffman - BMO Capital Markets Michael Ryskin - Bank of America Securities, Inc. Matthew Hewitt - Craig-Hallum Capital Group Joseph Catanzaro - Piper Sandler Chris Shibutani - Goldman Sachs & Co. Operator Welcome to Schrödinger's Conference Call to review Third Quarter 2023 Financial Results. My name is Eric and I will be your operator for today's call.
seekingalpha.com
Read More
Compared to Estimates, Schrodinger, Inc. (SDGR) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Schrodinger, Inc. (SDGR) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
Read More
Schrödinger Reports Third Quarter 2023 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the quarter ended on September 30, 2023. “Schrodinger had an excellent third quarter marked by strong revenue growth and significant pipeline progress. More of our software customers are increasing the scale of their use of our technology, and we remain very confident about the outlook for.
businesswire.com
Read More
3 Bill Gates Stocks to Buy for Billionaire-Like Returns
When investors think of Bill Gates stocks, they inevitably come up with Microsoft (NASDAQ: MSFT ), the software company he co-founded with Paul Allen in 1975 in Albuquerque. However, as Gates has spent less time around Microsoft's business, the billionaire has significantly diversified his investment portfolio.
investorplace.com
Read More
This Artificial Intelligence (AI) Stock Is Powering the Biotech Revolution: Should You Invest?
Schrödinger has a physics-based platform that helps accelerate drug discovery. The company sells its software to other businesses and has its own drug pipeline.
fool.com
Read More
Schrödinger to Announce Third Quarter 2023 Financial Results on November 1
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will report third quarter 2023 financial results on November 1, 2023.
businesswire.com
Read More
Why Wall Street Thinks This Artificial Intelligence (AI) Stock Could Skyrocket 140% Over the Next 12 Months
This company uses AI to improve drug discovery for all of the 20 biggest biopharmaceutical companies. Even the most pessimistic analyst thinks the stock could jump nearly 32% over the next 12 months.
fool.com
Read More
3 Artificial Intelligence Stocks That Could Outperform the ‘Godfather of AI'
I don't think there is any debate on the point that Nvidia (NASDAQ: NVDA ) has established itself as the godfather of AI. As growth accelerates for Nvidia in a big addressable global market, the company's stock has skyrocketed by 220% year-to-date (YTD).
investorplace.com
Read More
7 Trailblazing AI Stocks to Buy on Any Weakness
The transformative power of artificial intelligence ( AI ) — with regards to drug makers and banks to oil companies to every firm that carries out intensive sales activities — is widely known. Yet in spite of all of these points, it appears that the Street — which has been much more focused on a one percentage point change in bond rates lately than the revolutionary power of AI — is giving very few AI stocks the credit they deserve.
investorplace.com
Read More
Schrodinger: Leading The AI Healthcare Revolution
Schrödinger is a leading AI drug discovery company with a comprehensive platform used by researchers and scientists worldwide. The company's flagship product, Maestro, integrates various proprietary software tools for molecular modeling and simulation. SDGR has experienced significant growth and has established itself as the industry standard in the AI revolution in healthcare.
seekingalpha.com
Read More
This AI Biotech Stock Is Already Profitable. Should You Buy It?
Schrödinger discovers new medicines using advanced technologies like AI. It has already helped a collaborator bring a pair of drugs to market.
fool.com
Read More
The Good And Bad: Allison Transmission & Schrodinger Inc.
See two of the featured stocks from this month's model portfolios.
forbes.com
Read More
3 AI Drug Discovery Stocks to Watch
Schrödinger uses AI to drive revenue for both of its segments. Recursion got a big boost from computer chipmaker Nvidia.
fool.com
Read More
Schrodinger: More Than An AI Bubble Stock
Schrodinger's stock has performed well this year due to AI hype and strength in its drug discovery business. While the company appears attractively valued from a long-term perspective, the tight financing environment is currently a headwind. Investor sentiment is likely to ebb and flow along with broader interest in AI, creating downside risk in the near term.
seekingalpha.com
Read More
7 Stocks the Big Money Is Buying Now
There's no foolproof method for making money in the stock market, and, in my view, no one should rely on any one technique for picking stocks. After all, using multiple criteria — including analyzing fundamentals, checking charts, and identifying macro trends — should increase one's chances of success.
investorplace.com
Read More
Biotech Breakthroughs: 3 Companies on the Cusp of Major Discoveries
Artificial intelligence is changing the drug-discovery process by making it much faster and cheaper. Traditionally, most biotech stock drug candidates fail.
investorplace.com
Read More
3 AI Stocks Billionaires Are Loading Up On
Many investors, including a significant number of very wealthy individuals and institutions, are becoming enthralled with AI stocks. According to Goldman Sachs (NYSE: GS ), up to $200 billion could be poured into the technology by 2025.
investorplace.com
Read More
Why Shares of Schrödinger Are Falling Thursday
Second-quarter revenue was down 9% year over year. Schrödinger increased revenue guidance for software revenue but decreased it for drug discovery.
fool.com
Read More
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.62 per share a year ago.
zacks.com
Read More
Schrödinger, Inc. (SDGR) Q2 2023 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Jaren Madden - SVP, IR & Corporate Affairs Ramy Farid - CEO Geoff Porges - CFO Karen Akinsanya - President R&D, Therapeutics Conference Call Participants Michael Yee - Jefferies David Lebowitz - Citigroup Evan Seigerman - BMO Capital Markets Vikram Purohit - Morgan Stanley Matt Hewitt - Craig-Hallum Gaurav Goparaju - Berenberg Capital Markets Michael Ryskin - Bank of America Joseph Catanzaro - Piper Sandler Chris Shibutani - Goldman Sachs Operator Thank you for standing by. Welcome to Schrödinger's Conference Call to review Second Quarter 2023 Financial Results.
seekingalpha.com
Read More
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.
marketbeat.com
Read More
Biotech & Healthcare Meet AI: Stocks Soar On Innovation Potential
But some stocks in the biotech category are rising for a reason that's more common with techs, such as chipmaker Nvidia Corp. NASDAQ: NVDA or Microsoft Corp. NASDAQ: MSFT, which has made a significant investment in OpenAI, developer of ChatGPT.
marketbeat.com
Read More
3 Cutting-Edge Biotech Stocks That Are Riding the AI Wave Like None Other
Recursion Pharmaceuticals just got Nvidia on board with its vision of AI for R&D. Ginkgo Bioworks is pairing AI with laboratory robotics to streamline R&D, too.
fool.com
Read More
Schrödinger to Announce Second Quarter 2023 Financial Results on August 2
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its second quarter 2023 financial results on Wednesday, August 2, 2023, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed under "News & Events" in the investors section of Schrödinger's website, https://ir.schrodinger.com/news-and-.
businesswire.com
Read More
Better AI Biotech Stock: Schrödinger vs. Recursion Pharmaceuticals
Schrödinger and Recursion Pharmaceuticals use AI to improve drug development. Neither one has proven its business model to be viable yet.
fool.com
Read More
This Artificial Intelligence Biotech Stock Is Crushing the Market, but Is It a Buy?
Schrödinger's stock is riding the surge of interest in AI. Its drug discovery software is already bringing in money.
None
Read More
Why These 3 Stocks Are the Best Ways to Play AI Right Now
Goldman Sachs recently asserted “that AI adoption could boost productivity growth by 1.5 percentage points per year over a 10-year period.” The venerable firm's estimate shows how tremendously valuable the technology can be to many companies.
investorplace.com
Read More
DPST And BTO: Schrodinger's Regional Banks
Regional Banks have all the characteristics of Schrodinger's Cat. They appear phenomenally cheap on current earnings. They are dead in the water when you price in a reasonable cost of funds.
seekingalpha.com
Read More